Our response to COVID-19

We're supporting people to maintain their wellbeing and manage isolation.


How are how are anti-inflammatory medications used for schizophrenia? 

Growing evidence suggests that inflammatory processes may contribute to the development of schizophrenia. This suggests a potential role for anti-inflammatory medications, such as non-steroidal agents (e.g., aspirin) which may be potentially useful therapeutic strategies, particularly in combination with ongoing antipsychotic medication.

What is the evidence for anti-inflammatory medications?

Moderate to high quality evidence finds medium-sized effects of greater improvement in overall and negative symptoms with adjunctive minocycline over placebo, and a small effect for improving positive symptoms. Moderate quality evidence suggests there may also be some improvement in executive functioning. There were no differences in depression, functioning, cognition, or extrapyramidal symptoms.

Moderate quality evidence suggests a small benefit of adjunctive aspirin for improving symptoms, and a medium-sized benefit of adjunctive celecoxib  in first-episode, but not chronic patients. Moderate to low quality evidence suggests adjunctive oestrogen and adjunctive N-acetylcysteine may also improve symptoms.

September 2019

Last updated at: 2:13 am, 2nd March 2020
To view documentation related to this topic download the files below
Fact Sheet Technical Commentary

NeuRA Libraries

Title Colour Legend:
Green - Topic summary is available.
Orange - Topic summary is being compiled.
Red - Topic summary has no current systematic review available.